IP Library Granted Patent US 7,993,896
Granted Patent B2
US 7,993,896 · App. 12/789,946 · Granted Aug 9, 2011

Patent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,993,896
App. No.
12/789,946
Granted
Aug 9, 2011
Kind
B2
Abstract

This invention relates to enzymatic removal of type A and B antigens from blood group A, B, and AB reactive cells in blood products, and thereby converting these to non-A and non-B reactive cells. The invention further relates to using unique α-N-acetylgalactosaminidases and α-galactosidases with superior kinetic properties for removing the immunodominant monosaccharides of the blood group A and B antigens and improved performance in enzymatic conversion of red blood cells. The preferred unique α-N-acetylgalactosaminidases and α-galactosidases exhibit the following characteristics: (i) exclusive, preferred or no less than 10% substrate specificity for the type A and B branched polysaccharide structures relative to measurable activity with simple mono- and disaccharide structures and aglycon derivatives hereof; (ii) optimal performance at neutral pH with blood group oligosaccharides and in enzymatic conversion of cells; and (iii) a favorable kinetic constant K m with mono- and oligosaccharide substrates. The conversion methods of the invention use significantly lower amounts of recombinant glycosidase enzymes than previous and result in complete sero-conversion of all blood group A and B red cells.

Claims (10)

1. An isolated Streptomyces griseoplanus α-galactosidase for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells in blood products, wherein the α-galactosidase has the following characteristics:

(i) active in red blood cell conversion at neutral pH, and

(ii) isolated and purified from a non-recombinant strain of Streptomyces griseoplanus, wherein said α-galactosidase enzyme is isolatable by a method comprising the steps of:

(1) fermentation culturing of an α-galactosidase producing Streptomyces griseoplanus strain;

(2) disrupting the cultured Streptomyces griseoplanus strain of step (1);

(3) isolating an α-galactosidase-containing supernatant fraction from the disrupted Streptomyces griseoplanus strain of step (2) by centrifugation;

(4) treating the α-galactosidase-containing supernatant fraction of step (3) with ammonium sulfate to yield a 20 to 60 percent ammonium sulfate fraction enriched in the α-galactosidase;

(5) purifying the α-galactosidase from the 20 to 60 percent ammonium sulfate fraction of step (4) by anion exchange chromatography followed by cation exchange chromatography to yield an ion exchange purified α-galactosidase; and

(6) fractionating the ion exchange purified α-galactosidase of step (5) by size-exclusion chromatography to yield a purified α-galactosidase which elutes with a molecular weight in the range of 40-80 kD.

2. The isolated Streptomyes griseoplanus α-galactosidase of claim 1 wherein the enzyme is isolated from Streptomyces griseoplanus, ATCC Deposit No. PTA-4077.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2025
From: ANTOINETTE G. GIUGLIANO PC
To: VELICO MEDICAL, INC
Reel/Frame 073377/0224 →
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2020
From: PIERCE ATWOOD LLP
To: VELICO MEDICAL, INC.
Reel/Frame 053305/0343 →
SECURITY INTEREST Recorded Jun 27, 2014
From: VELICO MEDICAL, INC.
To: PIERCE ATWOOD LLP
Reel/Frame 033246/0316 →
SECURITY INTEREST Recorded Apr 18, 2014
From: VELICO MEDICAL, INC.
To: ANTOINETTE G. GIUGLIANO, PC DBA AGG INTELLECTUAL PROPERTY LAW
Reel/Frame 032713/0045 →
CHANGE OF NAME Recorded Apr 14, 2011
From: ZYMEQUEST, INC.
To: VELICO MEDICAL, INC.
Reel/Frame 026131/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2011
From: CLAUSEN, HENRIK; DE LA VEGA, HUMBERTO; HILL, CHERYL; LIU, QIYONG PETER
To: ZYMEQUEST, INC.
Reel/Frame 026115/0476 →